Actuate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	16.92	8.64	2.96	20.45
Cash & Short-Term Investments	16.92	8.64	2.96	20.45
Cash Growth	25.15%	192.08%	-85.53%	-
Other Current Assets	0.52	0.57	0.04	0.03
Total Current Assets	17.44	9.21	3	20.48
Other Long-Term Assets	0.27	0.11	-	-
Total Assets	17.71	9.32	3	20.48
Accounts Payable	1.25	1.92	3.42	2.13
Accrued Expenses	5.11	6.81	3.5	2.21
Other Current Liabilities	0.02	0.07	-	-
Total Current Liabilities	6.37	8.8	6.92	4.34
Other Long-Term Liabilities	0.4	0.41	1.52	1.31
Total Long-Term Liabilities	0.4	0.41	1.52	1.31
Total Liabilities	6.78	9.21	8.44	5.65
Common Stock	0	0	0	0
Additional Paid-in Capital	160.99	132.48	5.47	5.04
Retained Earnings	-150.05	-132.38	-105.09	-80.35
Total Common Shareholders' Equity	10.94	0.1	-99.63	-75.31
Minority Interest	-	-	94.18	90.14
Shareholders' Equity	10.94	0.1	-5.45	14.83
Total Liabilities & Equity	17.71	9.32	3	20.48
Net Cash (Debt)	16.92	8.64	2.96	20.45
Net Cash Growth	95.85%	192.08%	-85.53%	-
Net Cash Per Share	0.84	1.03	2.06	-
Book Value	10.94	0.1	-99.63	-75.31
Book Value Per Share	0.55	0.01	-69.43	-
Tangible Book Value	10.94	0.1	-99.63	-75.31
Tangible Book Value Per Share	0.55	0.01	-69.43	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q